@article{b642067a6e89414d8b391dfff6ccb46d,
title = "Targeting sleep disruption using sodium oxybate in chronic cluster headache prophylaxis",
author = "Silberstein, {Stephen D.} and Robbins, {Matthew S.}",
note = "Funding Information: Dr. Silberstein serves on scientific advisory boards for AGA Medical Corporation, Allergan, Inc., Amgen, Boston Scientific, CAPNIA, Coherex Medical, CoLucid Pharmaceuticals, CyDex Pharmaceuticals, Inc., GlaxoSmithKline, Eli Lilly and Company, MAP Pharmaceuticals, Inc., Medtronic, Inc., Merck Serono, Minster Pharmaceuticals plc, Neuralieve Inc., the NIH/NINDS, NuPathe Inc., Pfizer Inc, St. Jude Medical, and Valeant Pharmaceuticals International; serves on the editorial boards of Cephalalgia and Current Pain and Headache Reports; serves on the speakers' bureaus for Endo Pharmaceuticals, GlaxoSmithKline, and Merck; serves as a consultant for Amgen, Novartis, Opti-Nose, and Sepracor Inc.; his employer receives research support from AGA, Allergan, Boston Scientific, CAPNIA, Coherex, Endo, GlaxoSmithKline, Lilly, MAP, Medtronic, Merck, the NIH/NINDS, NuPathe, St. Jude Medical, Valeant, and Zogenix, Inc.; and receives research support from the American Headache Society and the International Headache Society. Dr. Robbins reports no disclosures.",
year = "2011",
month = jul,
day = "5",
doi = "10.1212/WNL.0b013e3182231445",
language = "English (US)",
volume = "77",
pages = "16--17",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",
}